复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

休市中 05-09 16:08:07

35.250

-0.250

-0.70%

最高36.600	最低35.000	成交量109.20万
今开35.300	昨收35.500	日振幅4.51%
总市值191.58亿	流通市值57.46亿	总股本5.43亿
成交额3,916万	换手率0.67%	流通股本1.63亿
市净率5.92	ROE31.52%	每股收益1.62
52周最高40.400	52周最低15.200	市盈率21.73
股息0.00	股息收益率0.00	ROA5.28%

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":35.25,"timestamp":1746778087016,"preClose":35.5,"halted":0,"volume":1091992,"delay":0,"floatShares":163000000,"shares":543494853,"eps":1.6218456008401074,"marketStatus":"休市中","change":-0.25,"latestTime":"05-09 16:08:07","open":35.3,"high":36.6,"low":35,"amount":39160941,"amplitude":0.04507,"askPrice":35.45,"askSize":1600,"bidPrice":35.25,"bidSize":5200,"shortable":3,"etf":0,"ttmEps":1.6218456008401074,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747013400000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":35.5,"openAndCloseTimeList":[[1746754200000,1746763200000],[1746766800000,1746777600000]],"volumeRatio":1.3416806466716693,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2533948172","title":"复宏汉霖盘中异动 股价大跌5.05%报34.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533948172","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533948172?lang=zh_cn&edition=full","pubTime":"2025-05-08 11:25","pubTimestamp":1746674733,"startTime":"0","endTime":"0","summary":"2025年05月08日早盘11时25分，复宏汉霖股票出现波动，股价快速下挫5.05%。截至发稿，该股报34.750港元/股，成交量25.4万股，换手率0.16%，振幅5.33%。资金方面，该股资金流入331.095万港元，流出483.287万港元。机构评级方面，在所有2家参与评级的机构中，50%的券商给予买入建议，50%的券商给予持有建议，无券商给予卖出建议。复宏汉霖股票所在的生物技术行业中，整体涨幅为0.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508112533aa2c86ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508112533aa2c86ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2533967236","title":"复宏汉霖05月07日遭主力抛售189.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533967236","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533967236?lang=zh_cn&edition=full","pubTime":"2025-05-07 16:15","pubTimestamp":1746605727,"startTime":"0","endTime":"0","summary":"05月07日, 复宏汉霖股价跌1.21%，报收36.60元，成交金额2980.2万元，换手率0.50%，振幅6.21%，量比1.08。复宏汉霖今日主力资金净流出189.1万元，上一交易日主力净流出270.7万元。该股近5个交易日下跌3.04%，主力资金累计净流入255.7万元；近20日主力资金累计净流入3852.3万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507171020a4752172&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507171020a4752172&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2531084730","title":"复宏汉霖与山德士达成HLX13全球商业化合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2531084730","media":"iDoNews","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531084730?lang=zh_cn&edition=full","pubTime":"2025-04-30 17:49","pubTimestamp":1746006542,"startTime":"0","endTime":"0","summary":"4月29日，复宏汉霖宣布与山德士签署授权协议，授予后者其自主研发的伊匹木单抗生物类似药HLX13在欧美、日本等主要市场的独家商业化权益。根据协议，复宏汉霖将主导HLX13的研发、生产及供应，并有望通过里程碑付款获得3.01亿美元收入，首付款达3100万美元。HLX13作为复宏汉霖核心生物类似药管线产品，其原研药Yervoy是全球首个CTLA-4抑制剂，已获批用于治疗黑色素瘤、肝细胞癌等多种适应症。此次合作将加速HLX13的全球市场布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043017512494e8cef2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043017512494e8cef2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2531080707","title":"复宏汉霖04月30日获主力加仓227.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531080707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531080707?lang=zh_cn&edition=full","pubTime":"2025-04-30 16:15","pubTimestamp":1746000913,"startTime":"0","endTime":"0","summary":"04月30日, 复宏汉霖股价涨1.56%，报收38.95元，成交金额3104.8万元，换手率0.49%，振幅7.04%，量比1.11。复宏汉霖今日主力资金净流入227.5万元，上一交易日主力净流入113.9万元。该股近5个交易日上涨2.25%，主力资金累计净流入1512.6万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2576.6万元，其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170249a6ce9815&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170249a6ce9815&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":1},{"id":"2531605177","title":"复宏汉霖与山德士就伊匹木单抗生物类似药达成授权合作，总金额超3亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531605177","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531605177?lang=zh_cn&edition=full","pubTime":"2025-04-29 23:38","pubTimestamp":1745941080,"startTime":"0","endTime":"0","summary":"根据协议条款，复宏汉霖将负责HLX13的研发、生产以及商业化供应，并从交易中获得3.01亿美元的潜在收入，其中3100万美元为交易首付款。作为全球仿制药与生物类似药领域的领导者，山德士始终以\"让健康触手可及\"为使命，凭借约1,300款产品累计惠及全球9亿患者。此次复宏汉霖携手山德士，将充分借力其成熟的全球网络与生物类似药商业化优势，加速HLX13在全球主流生物药市场的可及性。此次与山德士的合作，将进一步提升公司产品的全球可及性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4675725_ZH75725_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4007","BK1161","02696","SDZNY"],"gpt_icon":0},{"id":"2531736680","title":"复星医药最新公告：控股子公司复宏汉霖与SandozAG签署许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2531736680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531736680?lang=zh_cn&edition=full","pubTime":"2025-04-29 20:39","pubTimestamp":1745930368,"startTime":"0","endTime":"0","summary":"复星医药公告称，公司控股子公司复宏汉霖与SandozAG签订《合作与许可协议》，复宏汉霖授予SandozAG于许可区域及领域开发、生产及商业化其在研产品HLX13的权利。SandozAG需支付至多19,100万美元的款项，包括首付款和开发里程碑款项。同时，SandozAG需按约定百分比向复宏汉霖支付利润分成款。该协议自签署之日起生效，有效期至许可产品于许可区域首次商业化销售之日起15年，可自动续期5年。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900038885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0060","BK1515","BK0187","BK1161","BK0188","BK1191","02696","BK0028","600196","BK0196","BK0096","BK0012","BK1593","BK0239","02196","BK0175"],"gpt_icon":0},{"id":"2531613733","title":"复星医药(02196)控股子公司复宏汉霖与 Sandoz AG 签订《合作与许可协议》","url":"https://stock-news.laohu8.com/highlight/detail?id=2531613733","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531613733?lang=zh_cn&edition=full","pubTime":"2025-04-29 20:21","pubTimestamp":1745929296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，本公司控股子公司复宏汉霖与 Sandoz AG 签订《合作与许可协议》，由复宏汉霖授予 Sandoz AG 于许可区域及许可领域开发、生产及商业化其在研产品 HLX13的权利。HLX13系复宏汉霖自主研发的伊匹木单抗生物类似药，拟用于治疗黑色素瘤、肾细胞癌、结直肠癌、肝细胞癌、非小细胞肺癌、恶性胸膜间皮瘤及食管鳞状细胞癌。截至本公告日期，HLX13 于中国境内处于 I 期临床研究阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0183","BK0012","BK0096","BK1191","02196","BK1515","BK0188","BK1161","02696","BK0187","BK0060","BK0028","BK0175","600196","AG","BK0196","BK4210","BK1593"],"gpt_icon":0},{"id":"2531736358","title":"复星医药控股子公司复宏汉霖与 Sandoz AG签订《合作与许可协议》","url":"https://stock-news.laohu8.com/highlight/detail?id=2531736358","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531736358?lang=zh_cn&edition=full","pubTime":"2025-04-29 20:21","pubTimestamp":1745929260,"startTime":"0","endTime":"0","summary":"复星医药子公司复宏汉霖与Sandoz AG签订协议，授权其在多个国家和地区开发、生产及商业化在研产品HLX13，用于治疗多种癌症。HLX13在中国处于I期临床研究阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429202714974a265b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429202714974a265b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02196","BK1161","BK1191","02696","BK1593"],"gpt_icon":0},{"id":"2531911202","title":"复宏汉霖：就HLX13(重组抗CTLA-4全人单克隆抗体注射液)与Sandoz订立的许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2531911202","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531911202?lang=zh_cn&edition=full","pubTime":"2025-04-29 17:59","pubTimestamp":1745920768,"startTime":"0","endTime":"0","summary":"格隆汇4月29日丨复宏汉霖公告，近日，公司与Sandoz AG订立一份许可协议，据此，公司向Sandoz授出独家许可，供其于美国、约定的欧洲地区、日本、澳大利亚及加拿大内及领域内商业化HLX13。2023年12月，HLX13在中国健康男性受试者中开展的1期临床研究完成首例受试者给药。本次与Sandoz订立许可协议有助于深化公司产品的出海进程，进一步提升公司产品在国际市场的可及性和影响力，并有望为区域内患者提供更多治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042917594194e758d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042917594194e758d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2531017882","title":"复宏汉霖(02696)就HLX13(重组抗CTLA-4全人单克隆抗体注射液)与Sandoz订立的许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2531017882","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531017882?lang=zh_cn&edition=full","pubTime":"2025-04-29 17:42","pubTimestamp":1745919752,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，公司与Sandoz AG订立一份许可协议，据此，公司向Sandoz授出独家许可，供其于美国、约定的欧洲地区(42个欧洲国家)、日本、澳大利亚及加拿大内及领域内商业化HLX13(重组抗CTLA-4全人单克隆抗体注射液)。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287448.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2531296795","title":"智通港股早知道 | 工信部发布2025年汽车标准化工作要点 超前开展飞行汽车等新业态标准化需求研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2531296795","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531296795?lang=zh_cn&edition=full","pubTime":"2025-04-29 07:25","pubTimestamp":1745882740,"startTime":"0","endTime":"0","summary":"工信部发布2025年汽车标准化工作要点：超前开展飞行汽车等新业态标准化需求研究工信部发布2025年汽车标准化工作要点。其中提出，前瞻布局前沿领域标准研究。分析评估前沿技术发展趋势和潜在应用场景，识别研判未来汽车标准化发展方向，推动制定及发布车用人工智能、固态电池、电动汽车换电等标准子体系，启动数据治理及应用等新领域标准体系建设，超前开展飞行汽车等新业态标准化需求研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287034.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","BK1576","06127","02359","HSCEI","LU2242644610.SGD","03908","06855","LU2045819591.USD","SG9999002828.SGD","LU0708995583.HKD","BK1516","BK1564","BK1583","HSTECH","BK1574","LU0320764599.SGD","YANG","02696","LU0052750758.USD","BK4614","HK0000320223.HKD","HK0000306701.USD","BK1147","LU1046422090.SGD","HK0000320264.USD","LU2125910500.SGD","BK1161","01548","BK1141","BK1501"],"gpt_icon":1},{"id":"2530471728","title":"复宏汉霖(02696)：HLX22联合XELOX一线治疗HER2阳性局部晚期或转移性胃食管交界部和胃癌的国际多中心3期临床试验申请于德国获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2530471728","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530471728?lang=zh_cn&edition=full","pubTime":"2025-04-28 19:01","pubTimestamp":1745838119,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 公布，近日，HLX22联合曲妥珠单抗和化疗对比曲妥珠单抗和化疗 联合或不联合帕博利珠单抗一线治疗HER2阳性局部晚期或转移性胃食管交界部和胃癌的国际多中心3期临床试验申请于德国获批。公司拟于条件具备后于德国及其他欧盟国家开展临床试验。据悉，HLX22为公司许可引进并后续自主研发的新型靶向HER2的单克隆抗体，潜在适应症包括胃癌和乳腺癌等实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696","BK1583","03347","BK1576","BK1141"],"gpt_icon":0},{"id":"2530499178","title":"复宏汉霖盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530499178","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530499178?lang=zh_cn&edition=full","pubTime":"2025-04-28 09:41","pubTimestamp":1745804461,"startTime":"0","endTime":"0","summary":"2025年04月28日早盘09时41分，复宏汉霖股票出现异动，股价急速下跌5.02%。复宏汉霖股票所在的生物技术行业中，整体跌幅为2.50%。消息层面，截至09时41分，《复宏汉霖就H药与Lotus达成韩国独家授权合作 总金额超1.12亿美元》资讯为影响复宏汉霖的重要信息。复宏汉霖全速推进H药在全球市场的商业化进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428094101a469c23e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428094101a469c23e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2530131266","title":"每日卖空追踪 | 复宏汉霖 04月25日卖空量成交3.87万股，卖空比例为8.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530131266","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530131266?lang=zh_cn&edition=full","pubTime":"2025-04-25 21:32","pubTimestamp":1745587933,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间04月25日，跌2.82%，卖空量成交3.87万股，较上一交易日增加2.11%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425213214a6c81d3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425213214a6c81d3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2530188020","title":"复星医药最新公告：控股子公司复宏汉霖与Alvogen Korea签署许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2530188020","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530188020?lang=zh_cn&edition=full","pubTime":"2025-04-25 18:41","pubTimestamp":1745577678,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖授予Alvogen Korea在韩国及广泛期小细胞肺癌（ES-SCLC）、非鳞状非小细胞肺癌（nsNSCLC）、转移性结直肠癌（mCRC）、胃癌（GC）和食管鳞状细胞癌（ESCC）适应症独家商业化斯鲁利单抗注射液的权利。协议包括至多1,450万美元的付款，以及至多9,750万美元的商业销售里程碑款项。许可产品于许可区域的开发、注册及销售等还须得到相关监管机构的批准，存在不确定性。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500032181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0060","BK1515","BK0187","BK1161","BK0188","BK1191","02696","BK0028","600196","BK0196","BK0096","BK0012","BK1593","BK0239","02196","BK0175"],"gpt_icon":0},{"id":"2530904061","title":"复宏汉霖拟向Alvogen Korea授出独家许可，供其于韩国于领域内商业化汉斯状®","url":"https://stock-news.laohu8.com/highlight/detail?id=2530904061","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530904061?lang=zh_cn&edition=full","pubTime":"2025-04-25 17:57","pubTimestamp":1745575048,"startTime":"0","endTime":"0","summary":"格隆汇4月25日丨复宏汉霖宣布，公司于2025年4月25日与Alvogen Korea订立一份许可协议，据此，公司向Alvogen Korea授出独家许可，供其于韩国于领域内商业化汉斯状。同时，汉斯状亦已分别于欧盟、印度尼西亚、柬埔寨、泰国获批上市。汉斯状在中国大陆境内的销售推广由本公司自建商业化团队主导。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251757289744d8b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251757289744d8b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0},{"id":"2530901857","title":"复宏汉霖：授予Alvogen Korea汉斯状独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2530901857","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530901857?lang=zh_cn&edition=full","pubTime":"2025-04-25 17:47","pubTimestamp":1745574448,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"2530901891","title":"复宏汉霖(02696)就汉斯状®与Alvogen Korea订立许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2530901891","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530901891?lang=zh_cn&edition=full","pubTime":"2025-04-25 17:47","pubTimestamp":1745574427,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，公司于2025年4月25日与Alvogen Korea Co., Ltd.订立一份许可协议，据此，公司向 Alvogen Korea授出独家许可，供其于韩国于领域内商业化汉斯状® (斯鲁利单抗注射液)。本次合作将有助于进一步拓展公司产品的海外市场，增强公司产品在国际市场的可及性和认可度，并为公司收入的持续提升创造条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161"],"gpt_icon":0},{"id":"1166357920","title":"港股异动 | 生物医药板块持续高开，康方生物涨5%，本周已累涨近30%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166357920","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166357920?lang=zh_cn&edition=full","pubTime":"2025-04-25 09:27","pubTimestamp":1745544452,"startTime":"0","endTime":"0","summary":"本周五（4月25日）港股盘初，生物医药板块持续高开， $康方生物(09926)$ 涨5%，本周已累涨近30%， $云顶新耀-B(01952)$ 涨近5%：","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","03759","02359","02696","06160","02269","06622","06996","06606","03347","09995","06185","06127","00241","06618"],"gpt_icon":0},{"id":"2529304739","title":"每日卖空追踪 | 复宏汉霖 04月24日卖空量成交3.79万股，卖空比例为4.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529304739","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529304739?lang=zh_cn&edition=full","pubTime":"2025-04-24 21:21","pubTimestamp":1745500897,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间04月24日，涨3.32%，卖空量成交3.79万股，较上一交易日增加13.13%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424212139a4656c53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424212139a4656c53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02696"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1264},{"period":"1month","weight":0.377},{"period":"3month","weight":0.7581},{"period":"6month","weight":0.6786},{"period":"1year","weight":1.0784},{"period":"ytd","weight":0.4873}],"compareEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":0.1285},{"period":"3month","weight":0.0821},{"period":"6month","weight":0.1032},{"period":"1year","weight":0.2336},{"period":"ytd","weight":0.14}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。该公司的主要产品包括利妥昔单抗注射液HLX01（汉利康）、赫赛汀（曲妥珠单抗）生物类似药HLX02、修美乐（阿达木单抗）生物类似药HLX03和安维汀（贝伐珠单抗）生物类似药HLX04以及候选生物创新药，包括HLX06（一种新型VEGFR2抑制剂）、HLX07（一种EGFR抑制剂）、HLX10（一种新型PD-1抑制剂）、HLX20（一种新型PD-L1抑制剂）及HLX22（一种新型HER2抑制剂）等。该公司还提供相关技术服务。该公司主要在中国境内和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.052523},{"month":2,"riseRate":0.666667,"avgChangeRate":0.108951},{"month":3,"riseRate":0.5,"avgChangeRate":-0.016995},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.073264},{"month":6,"riseRate":0.6,"avgChangeRate":0.1049},{"month":7,"riseRate":0.4,"avgChangeRate":0.0182},{"month":8,"riseRate":0.4,"avgChangeRate":-0.051626},{"month":9,"riseRate":0,"avgChangeRate":-0.146246},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.017718},{"month":11,"riseRate":0.666667,"avgChangeRate":0.070363},{"month":12,"riseRate":0.833333,"avgChangeRate":0.001179}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}